TMCnet News
Preliminary Results from Clinical Study Evaluating Use of Quell in Chemotherapy-Induced Peripheral Neuropathy to be presented at the American Pain Society Annual MeetingNeuroMetrix, Inc. (Nasdaq: NURO) today reported that researchers from the University of Rochester School of Medicine and Dentistry will present a scientific poster titled "Wearable TENs band for chemotherapy-induced peripheral neuropathy (CIPN): A feasibility study" at the upcoming annual meeting of the American Pain Society to be held in Pittsburgh, PA, May 17-20. Chemotherapy-induced peripheral neuropathy (CIPN) is a common cause of chronic neuropathic pain. It is characterized by symptoms that include burning pain, a distorted sense of touch, numbness, tingling, and cramps. CIPN is a common dose limiting side effect of chemotherapy and significantly impacts the quality of life of many cancer survivors. About one-third of patients will develop chronic CIPN 6 months or more after the end of chemotherapy, The Quell® study was led by Dr. Jennifer Gewandter, Assistant Professor, Department of Anesthesiology. The objective of the study was to test the feasibility of evaluating Quell technology in cancer survivors with CIPN and to obtain preliminary clinical efficacy data. "We are pleased to have supported this study, and hope it lays the groundwork for a large scale randomized clinical study that further evaluates the efficacy of Quell in CIPN," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "Many Quell users have neuropathic pain, including from CIPN. We therefore hope that this and future studies help u optimize Quell for treatment of chronic neuropathic pain."
About Quell
About NeuroMetrix
View source version on businesswire.com: http://www.businesswire.com/news/home/20170515005158/en/ |